The new analysis compares people taking GLP-1 medications with those on a different class of diabetes drugs and finds fewer cases of epilepsy among the GLP-1 group. Observational studies can reveal meaningful signals, but they cannot prove why those signals appear. Careful clinical trials and biological studies are needed to learn whether the medications change seizure thresholds, reduce inflammation, or work through another mechanism that influences brain circuitry.
If this association holds up, the implications reach beyond diabetes care. A treatment that strengthens brain resilience would affect aging, cognitive health, and efforts to make neurological care more equitable. Follow-up research could clarify who benefits most and whether these medications can safely be repurposed to support brain health. Read the full paper to explore how this line of inquiry might reshape approaches to human potential and inclusive health.
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous long-term studies are needed to understand the link.
